has been cited by the following article(s):
[1]
|
Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial
The Lancet Gastroenterology & Hepatology,
2022
DOI:10.1016/S2468-1253(21)00399-X
|
|
|
[2]
|
Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial
The Lancet Gastroenterology & Hepatology,
2022
DOI:10.1016/S2468-1253(21)00399-X
|
|
|
[3]
|
Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?
International Journal of Infectious Diseases,
2021
DOI:10.1016/j.ijid.2021.04.061
|
|
|